← 產業報告目錄

Active Pharmaceutical Ingredients (API) Market by type (Innovative, Generic), Synthesis (synthetic, biotech), Potency (HPAPI), Product (mAbs, hormones), Drug (OTC, Rx), Application (Diabetes, Oncology), Competitive landscape - Global forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-10-15頁數 578報告編號 PH1262

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global active pharmaceutical ingredients market is projected to reach USD 198.39 billion by 2030 from an estimated USD 144.20 billion in 2025, at a CAGR of 6.6% from 2025 to 2030. The expansion of the active pharmaceutical ingredients market has been predominantly fueled by the expanding oncology & rare disease and diabetes product pipeline. Over the past few years, type 2 diabetes and obesity care have been reshaped by a new class of peptide-based drugs, most notably Semaglutide, Tirzepatide, Liraglutide, and Dulaglutide. These therapies are transforming patient outcomes and creating significant opportunities across the API supply chain. The pharmaceutical & biotechnology industry segment accounted for the largest share by end user in 2024. Based on end users, the market is categorized into the pharmaceutical & biotechnology industry, contract research organizations (CROs), contract manufacturing organizations (CMOs), and other end users. The pharmaceutical & biotechnology industry accounted for the major end-user of active pharmaceutical ingredients (APIs), which are essential for drug development and manufacturing. The pharmaceutical industry has seen increasing manufacturing outsourcing to CMOs in the last 5 years, especially for developing and manufacturing drugs & biologics, such as high-potency drugs, ADCs, among others. However, pharmaceutical and biotechnology companies still dominate the end-user segment by retaining in-house manufacturing for high-value blockbuster drugs and biologics. Additionally, the rising demand for innovative therapies has encouraged continuous investment in research and development, with companies prioritizing the creation of novel drugs and advanced formulations. Together, these trends are expected to further strengthen the growth of the pharmaceutical and biotechnology end-user segment. The innovative APIs segment accounted for the largest market share in the active pharmaceutical ingredients market by type. Based on type, the global active pharmaceutical ingredients (API) market is divided into innovative APIs and generic APIs. In 2024, innovative APIs dominated the market, driven by the increasing number of regulatory approvals for new and advanced drugs, which is expected to continue supporting growth over the forecast period. For instance, the US FDA approved more than 50 new molecular entities (NMEs) in 2024, reflecting the rising pace of novel drug development. Innovative APIs, being protected by patents, are typically priced higher than generic APIs, contributing to their larger market share. The segment’s growth is further reinforced by the focus of pharmaceutical and biotechnology companies on developing novel therapies for complex and unmet medical needs, including oncology, rare diseases, and biologics. Additionally, investments in research and development, advanced manufacturing capabilities, and regulatory incentives continue to promote the introduction of innovative APIs. These factors position innovative APIs as the leading segment of the global API market, reflecting higher value and strong demand. The Asia Pacific region is expected to grow at the highest CAGR in the global active pharmaceutical ingredients market during the forecast period. The market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific region is projected to grow at the highest CAGR during the forecast period. The key factors contributing to market growth include the increasing adoption and demand for high-value therapies, driving manufacturing expansion by global & regional players. In addition, the expansion of CDMOs in the region, which is focused on synthetic and biological therapies, is also helping drive demand for APIs. China, Japan, South Korea, India, and Australia are witnessing the growing adoption of innovative and generic medicine, which is supported by expanding manufacturing facilities in the Asia Pacific region. Furthermore, a combination of cost-efficient manufacturing, expanding generics and biosimilars production, and strong government support for local API manufacturing to reduce dependency on imports. India and China are emerging as global hubs owing to their large-scale production capacity, skilled workforce, and favorable regulatory initiatives, which support the growth of the active pharmaceutical ingredients market in the region. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side- 70% and Demand Side- 30% • By Designation: Managers- 45%, CXOs and Directors- 30%, and Executives- 25% • By Region: North America- 30%, Europe- 30%, Asia Pacific- 30%, Latin America- 5%, and the Middle East & Africa- 5% Key Companies Key players in the active pharmaceutical ingredients market include Pfizer (CentreOne) (US), Teva Pharmaceutical Industries Ltd. (Israel), Divi’s Laboratories Limited (India), Sandoz Group AG (Switzerland), SK Inc. (South Korea), Merck KGaA (Germany), Dr. Reddy’s Laboratories Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cipla (India), Aurobindo Pharma (India), Evonik Industries AG (Germany), Hikma Pharmaceuticals plc (UK), BASF SE (Germany), Alembic Pharmaceuticals Limited (India), Siegfried Holding AG (Switzerland), EUROAPI (France), Asymchem (China), Bachem (Switzerland), Zhejiang Huahai Pharmaceutical Co., Ltd. (China), and Zhejiang Hisun (China). Research Coverage This research report categorizes the active pharmaceutical ingredients market, Active Pharmaceutical Ingredient Market by type (Innovative, generic), potency (traditional API, highly potent API (synthetic, biologics), synthesis ((synthetic, biotech), products (mAb, hormones, cytokines) expression system), type of drug (OTC, Rx), therapeutics application (diabetes, oncology, CVD), end user (pharma & biotech, CROs CMOs) and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the active pharmaceutical ingredients market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the active pharmaceutical ingredients market. Reasons to buy this report The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the overall active pharmaceutical ingredients market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (Surge in Demand for Complex APIs, Government Incentives & Supply Chain Reshoring, Adoption of Continuous Manufacturing & Digital Process Controls, Expanding Oncology & Rare Disease Pipeline Driving Outsourcing), restraints (Tightening regulatory requirements, high production costs in Western facilities and price pressure from generic tenders and single-winner procurement policies), opportunities (Critical medicines are commanding premium pricing through dual-sourcing and local manufacturing, China-Plus-One Strategy Boosting India, US, & EU Manufacturing Bases, and Integrated API-to-FDF CDMO Service Models Gaining Traction), and challenges (Supply Chain Concentration Risk, Quality Failures & Site Shutdowns Leading to Global Supply Disruptions, Capital-intensive Investments Needed for High-containment & Advanced Facilities and Geopolitical Tensions & Trade Restrictions Impacting API Flow) • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the active pharmaceutical ingredients market • Market Development: Comprehensive information about lucrative markets across varied regions • Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the active pharmaceutical ingredients market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the active pharmaceutical ingredients market.
目錄 Table of Contents
1 INTRODUCTION 49 1.1 STUDY OBJECTIVES 49 1.2 MARKET DEFINITION 49 1.3 INCLUSIONS AND EXCLUSIONS 50 1.4 STUDY SCOPE 50 1.4.1 SEGMENTS CONSIDERED 51 1.4.2 YEARS CONSIDERED 52 1.5 CURRENCY CONSIDERED 52 1.6 STAKEHOLDERS 52 1.7 SUMMARY OF CHANGES 53 2 RESEARCH METHODOLOGY 54 2.1 RESEARCH DATA 54 2.1.1 SECONDARY DATA 55 2.1.1.1 Objectives of secondary research 55 2.1.1.2 Key data from secondary sources 56 2.1.2 PRIMARY DATA 56 2.1.2.1 Breakdown of primaries (supply- and demand-side participants) 57 2.1.2.2 Key objective of primary research 57 2.2 MARKET ESTIMATION 58 2.2.1 GLOBAL MARKET ESTIMATION 58 2.2.1.1 Company revenue analysis (Bottom-up approach) 58 2.2.1.1.1 Revenue share analysis of Pfizer, Inc. 59 2.2.1.2 MnM repository analysis 60 2.2.1.3 Primary interviews 60 2.2.2 INSIGHTS OF PRIMARY EXPERTS 61 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 61 2.3 GROWTH RATE PROJECTIONS 63 2.4 DATA TRIANGULATION 65 2.5 RESEARCH ASSUMPTIONS 66 2.6 RESEARCH LIMITATIONS 66 2.7 RISK ANALYSIS 67 3 EXECUTIVE SUMMARY 68 3.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 68 3.2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 68 3.3 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS 69 3.3.1 PHARMACEUTICAL CONTRACT MANUFACTURERS 69 3.3.2 STARTUPS AND INNOVATIVE BIOTECH FIRMS 69 3.3.3 CDMOS/CROS 69 4 PREMIUM INSIGHTS 76 4.1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET OVERVIEW 76 4.2 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE AND COUNTRY, 2025 77 4.3 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY TYPE 77 4.4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT 78 4.5 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 78 4.6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: EMERGING VS. DEVELOPED MARKETS, 2025 VS. 2030 79 4.7 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 79 4.8 EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFTS 80 4.9 VC/PRIVATE EQUITY INVESTMENT TRENDS AND STARTUP LANDSCAPE 80 4.10 REGULATORY POLICY INITIATIVES 81 5 MARKET OVERVIEW 82 5.1 INTRODUCTION 82 5.2 MARKET DYNAMICS 82 5.2.1 DRIVERS 84 5.2.1.1 Surge in demand for complex APIs 84 5.2.1.2 Favorable government incentives and supply chain reshoring 84 5.2.1.3 Increasing adoption of continuous manufacturing and digital process controls 85 5.2.1.4 Rapid growth of oncology and rare disease pipelines 86 5.2.2 RESTRAINTS 88 5.2.2.1 Tightening regulatory requirements for nitrosamine and impurity controls 88 5.2.2.2 High production costs in US and Europe-based facilities 89 5.2.2.3 Price pressure from generic tenders and single-winner procurement policies 89 5.2.3 OPPORTUNITIES 89 5.2.3.1 Growing emphasis on supply resilience and security of critical medicine manufacturing 89 5.2.3.2 China-Plus-One strategy 90 5.2.3.3 Increasing adoption of integrated CDMO service models 90 5.2.4 CHALLENGES 91 5.2.4.1 Capital-intensive investments for high containment and advanced facilities 91 5.2.4.2 Quality failures and site shutdowns 91 5.2.4.3 Supply chain concentration risk 91 5.2.4.4 Geopolitical tensions and trade restrictions 92 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 92 5.4 PRICING ANALYSIS 93 5.4.1 INDICATIVE PRICING ANALYSIS, BY KEY PLAYER, 2024 93 5.4.2 INDICATIVE PRICING ANALYSIS, BY REGION, 2024 95 5.5 TECHNOLOGY ANALYSIS 96 5.5.1 KEY TECHNOLOGIES 96 5.5.1.1 Continuous manufacturing 96 5.5.1.2 Advanced analytical techniques 97 5.5.1.3 Biocatalysis 97 5.5.2 COMPLEMENTARY TECHNOLOGIES 97 5.5.2.1 Data analytics and digitalization 97 5.5.2.2 Personalized medicines and custom synthesis 97 5.5.2.3 Supercritical fluid technology 98 5.5.3 ADJACENT TECHNOLOGIES 98 5.5.3.1 Supply chain visibility and blockchain 98 5.5.3.2 3D printing 98 5.5.3.3 Nanotechnology 99 5.6 SUPPLY CHAIN ANALYSIS 99 5.7 VALUE CHAIN ANALYSIS 100 5.7.1 RESEARCH & DEVELOPMENT (VALUE ADDITION: 30–35%) 101 5.7.2 CLINICAL TRIALS & REGULATORY APPROVALS (VALUE ADDITION: 50–70%) 102 5.7.3 MANUFACTURING (VALUE ADDITION: 70–80%) 102 5.7.4 MARKETING & COMMERCIALIZATION (VALUE ADDITION: 80–100%) 102 5.8 ECOSYSTEM ANALYSIS 102 5.9 KEY CONFERENCES & EVENTS 104 5.10 REGULATORY ANALYSIS 105 5.10.1 REGULATORY SCENARIO 106 5.10.1.1 North America 106 5.10.1.1.1 US 106 5.10.1.1.2 Canada 106 5.10.1.2 Europe 106 5.10.1.2.1 Germany 106 5.10.1.2.2 UK 107 5.10.1.3 Asia Pacific 107 5.10.1.3.1 Japan 107 5.10.1.4 Latin America 107 5.10.1.4.1 Brazil 107 5.10.1.5 Middle East & Africa 107 5.10.1.5.1 Saudi Arabia 107 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 108   5.11 PORTER’S FIVE FORCES ANALYSIS 110 5.11.1 THREAT OF NEW ENTRANTS 112 5.11.2 THREAT OF SUBSTITUTES 112 5.11.3 BARGAINING POWER OF SUPPLIERS 112 5.11.4 BARGAINING POWER OF BUYERS 112 5.11.5 INTENSITY OF COMPETITIVE RIVALRY 112 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 113 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 113 5.12.2 KEY BUYING CRITERIA 114 5.13 CASE STUDY ANALYSIS 115 5.14 MACROECONOMICS INDICATORS 116 5.14.1 HEALTHCARE EXPENDITURE TRENDS 116 5.14.2 GLOBAL CANCER BURDEN 117 5.15 PATENT ANALYSIS 118 5.15.1 LIST OF PATENTS 120 5.16 UNMET NEEDS AND WHITE SPACES 120 5.17 TRADE DATA 121 5.17.1 IMPORT DATA FOR HS CODE–2941 121 5.17.2 EXPORT DATA FOR HS CODE–2941 124 5.18 INVESTMENT AND FUNDING SCENARIO 127 5.19 MANUFACTURING SITES AND CAPACITY EXPANSION OF KEY API SUPPLIERS 128 5.20 IMPACT OF AI/GEN AI ON ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 131 5.20.1 INTRODUCTION 131 5.20.2 IMPACT AND MARKET POTENTIAL OF ARTIFICIAL INTELLIGENCE IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 131 5.20.3 AI USE CASES 132 5.20.4 FUTURE OF GENERATIVE AI IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET ECOSYSTEM 133 5.21 IMPACT OF US TARIFF ON ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 134 5.21.1 INTRODUCTION 134 5.21.2 KEY TARIFF RATES 134 5.21.3 PRICE IMPACT ANALYSIS 135 5.21.4 IMPACT ON COUNTRY/REGION 136 5.21.4.1 North America 136 5.21.4.1.1 US 136 5.21.4.2 Europe 136 5.21.4.3 Asia Pacific 136 5.21.5 IMPACT ON END-USE INDUSTRIES 136 5.21.5.1 Pharmaceutical & biotechnology industry 136 5.21.5.2 Contract research organizations (CROs) 137 5.21.5.3 Contract manufacturing organizations (CMOs) 137   6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 138 6.1 INTRODUCTION 139 6.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE (CAPTIVE AND MERCHANT) 139 6.3 INNOVATIVE APIS 140 6.3.1 INCREASING REGULATORY APPROVALS FOR INNOVATIVE DRUGS TO FACILITATE GROWTH 140 6.4 GENERIC APIS 144 6.4.1 GROWING FOCUS ON GENERIC DRUGS AND LOW MANUFACTURING COSTS TO FUEL MARKET 144 7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY 148 7.1 INTRODUCTION 149 7.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY POTENCY (CAPTIVE AND MERCHANT) 149 7.3 TRADITIONAL APIS 150 7.3.1 INCREASING NUMBER OF APPLICATIONS IN THERAPEUTIC AREAS TO AUGMENT GROWTH 150 7.4 HIGHLY POTENT APIS 154 7.4.1 SYNTHETIC 158 7.4.1.1 Evolving targeted oncology therapies to stimulate growth 158 7.4.2 BIOLOGICS 161 7.4.2.1 Robust product pipeline to encourage growth 161 8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS 165 8.1 INTRODUCTION 166 8.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT) 166 8.3 SYNTHETIC APIS 167 8.3.1 INNOVATIVE SYNTHETIC APIS 171 8.3.1.1 High value of innovative APIs to drive market 171 8.3.2 GENERIC SYNTHETIC APIS 175 8.3.2.1 Increasing need for generic medicines to contribute to growth 175 8.4 BIOTECH APIS 178 8.4.1 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 182 8.4.1.1 Innovative biotech APIs 182 8.4.1.1.1 Growing demand for innovative biopharmaceuticals to drive market 182 8.4.1.2 Generic biotech APIs 186 8.4.1.2.1 Cost-effectiveness and favorable government efforts to fuel market 186 8.4.2 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT 190 8.4.2.1 Monoclonal antibodies 190 8.4.2.1.1 Growing applications of antibody-drug conjugates in treating cancer to drive market 190 8.4.2.2 Hormones and growth factors 194 8.4.2.2.1 Growing incidence of hormonal disorders to drive market 194 8.4.2.3 Fusion proteins 197 8.4.2.3.1 Increasing applications of fusion proteins in biopharmaceuticals to aid growth 197 8.4.2.4 Cytokines 200 8.4.2.4.1 Rising use of cytokines in cell signaling, inflammation, and cell growth to spur growth 200 8.4.2.5 Therapeutic enzymes 203 8.4.2.5.1 Growing significance of enzymes in therapies for cancer and pain management to propel market 203 8.4.2.6 Blood factors and anti-coagulants 206 8.4.2.6.1 Growing incidence of hemophilia to fuel market 206 8.4.2.7 Recombinant vaccines 209 8.4.2.7.1 Growing prevalence of infectious diseases to fuel market 209 8.4.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM 212 8.4.3.1 Mammalian expression systems 213 8.4.3.1.1 Ability to carry post-translational modifications to drive adoption 213 8.4.3.2 Microbial expression systems 217 8.4.3.2.1 High expression levels of proteins at low costs to aid growth 217 8.4.3.3 Yeast expression systems 220 8.4.3.3.1 Efficient protein secretion and simple purification to contribute to growth 220 8.4.3.4 Insect expression systems 224 8.4.3.4.1 Scalability, cost-effectiveness, and favorable safety profile to boost market 224 8.4.3.5 Other expression systems 228 9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG 231 9.1 INTRODUCTION 232 9.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF DRUG (CAPTIVE AND MERCHANT) 232 9.3 PRESCRIPTION DRUGS 233 9.3.1 INCREASED ADOPTION OF SPECIALTY DRUGS TO SUPPORT GROWTH 233 9.4 OVER-THE-COUNTER DRUGS 237 9.4.1 RISING AWARENESS OF PRECAUTIONARY CARE AND HEALTH CONCERNS TO SPUR GROWTH 237 10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION 241 10.1 INTRODUCTION 242 10.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT) 242 10.3 COMMUNICABLE DISEASES 244 10.3.1 INCREASING INVESTMENTS IN DEVELOPING NEW ANTIBIOTICS, ANTIVIRALS, ANTIFUNGALS, AND VACCINES TO AID GROWTH 244 10.4 ONCOLOGY 247 10.4.1 GROWING NUMBER OF FDA APPROVALS TO DRIVE MARKET 247 10.5 DIABETES 251 10.5.1 RISING ADVANCEMENTS IN TREATMENT OPTIONS TO EXPEDITE GROWTH 251 10.6 CARDIOVASCULAR DISEASES 255 10.6.1 INCREASING ADOPTION OF GROWTH STRATEGIES BY KEY PLAYERS TO PROMOTE GROWTH 255 10.7 RESPIRATORY DISEASES 258 10.7.1 INCREASING BURDEN OF RESPIRATORY DISORDERS TO BOLSTER GROWTH 258 10.8 PAIN MANAGEMENT 262 10.8.1 RISING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS TO BOLSTER GROWTH 262 10.9 OTHER THERAPEUTIC APPLICATIONS 265 11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER 269 11.1 INTRODUCTION 270 11.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY END USER (CAPTIVE AND MERCHANT) 270 11.3 PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY 272 11.3.1 RISE IN NEED OF NOVEL TREATMENTS TO EXPEDITE GROWTH 272 11.4 CONTRACT RESEARCH ORGANIZATIONS 275 11.4.1 INCREASING OUTSOURCING OF DRUG R&D ACTIVITIES TO SUPPORT GROWTH 275 11.5 CONTRACT MANUFACTURING ORGANIZATIONS 279 11.5.1 GROWING FOCUS ON BETTER QUALITY AND REGULATORY COMPLIANCE TO DRIVE MARKET 279 11.6 OTHER END USERS 282 12 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION 286 12.1 INTRODUCTION 287 12.2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION (CAPTIVE AND MERCHANT) 287 12.3 NORTH AMERICA 289 12.3.1 MACROECONOMIC ANALYSIS OF NORTH AMERICA 290 12.3.2 US 296 12.3.2.1 High clinical trial & drug discovery activity and efficient regulatory environment to expedite growth 296 12.3.3 CANADA 301 12.3.3.1 Favorable government support and strong product pipeline to sustain growth 301 12.4 EUROPE 306 12.4.1 MACROECONOMIC ANALYSIS OF EUROPE 307 12.4.2 GERMANY 313 12.4.2.1 High healthcare expenditure and advanced R&D facilities to drive market 313 12.4.3 UK 318 12.4.3.1 Rising government investments and growing focus on personalized treatment to fuel market 318 12.4.4 FRANCE 323 12.4.4.1 Increased focus on domestic manufacturing to promote growth 323 12.4.5 ITALY 328 12.4.5.1 Rising commercial drug development to favor growth 328 12.4.6 SPAIN 333 12.4.6.1 Increase in generic drug manufacturing capacity to propel market 333 12.4.7 HUNGARY 338 12.4.7.1 Increasing manufacturing activities in pharmaceutical sector to drive market 338 12.4.8 REST OF EUROPE 343 12.5 ASIA PACIFIC 348 12.5.1 MACROECONOMIC ANALYSIS OF ASIA PACIFIC 349 12.5.2 CHINA 355 12.5.2.1 Rise in government policies to increase medicine access and affordability to support growth 355 12.5.3 JAPAN 360 12.5.3.1 Growing geriatric population to boost market 360 12.5.4 INDIA 365 12.5.4.1 Increasing R&D activities and rising government funding initiatives to favor growth 365 12.5.5 SOUTH KOREA 370 12.5.5.1 Rising annual drug exports to drive market 370 12.5.6 AUSTRALIA 375 12.5.6.1 Increasing demand for innovative APIs to propel market 375 12.5.7 REST OF ASIA PACIFIC 380 12.6 LATIN AMERICA 385 12.6.1 LATIN AMERICA: MACROECONOMIC ANALYSIS 385 12.6.2 BRAZIL 391 12.6.2.1 Increased government investments in pharmaceutical R&D to drive market 391 12.6.3 MEXICO 396 12.6.3.1 Rising investments by foreign firms to support market growth 396 12.6.4 REST OF LATIN AMERICA 401 12.7 MIDDLE EAST 406 12.7.1 MACROECONOMIC ANALYSIS OF MIDDLE EAST 406 12.7.2 ISRAEL 412 12.7.2.1 Highly educated workforce and strong culture of innovations to support growth 412 12.7.3 GCC COUNTRIES 417 12.7.3.1 Saudi Arabia 422 12.7.3.1.1 Growing healthcare expenditure to boost market 422 12.7.3.2 UAE 427 12.7.3.2.1 Rising demand for technologically advanced manufacturing processes to aid growth 427 12.7.3.3 Rest of GCC Countries 432 12.7.4 REST OF MIDDLE EAST 437 12.8 AFRICA 442 12.8.1 GROWING DEMAND FOR PHARMACEUTICAL PRODUCTS TO PROPEL MARKET 442 12.8.2 MACROECONOMIC OUTLOOK FOR AFRICA 442 13 COMPETITIVE LANDSCAPE 449 13.1 INTRODUCTION 449 13.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 449 13.3 REVENUE ANALYSIS, 2022–2024 451 13.4 MARKET SHARE ANALYSIS, 2024 452 13.5 COMPANY VALUATION AND FINANCIAL METRICS 454 13.5.1 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 455 13.6 BRAND/PRODUCT COMPARISON 456 13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 458 13.7.1 STARS 458 13.7.2 EMERGING LEADERS 458 13.7.3 PERVASIVE PLAYERS 458 13.7.4 PARTICIPANTS 458 13.7.5 COMPETITIVE BENCHMARKING, 2024 460 13.7.5.1 Company footprint 460 13.7.5.2 Region Footprint 461 13.7.5.3 Type footprint 462 13.7.5.4 Potency footprint 463 13.7.5.5 Therapeutic application footprint 464 13.8 COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 466 13.8.1 PROGRESSIVE COMPANIES 466 13.8.2 RESPONSIVE COMPANIES 466 13.8.3 DYNAMIC COMPANIES 466 13.8.4 STARTING BLOCKS 466 13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 468 13.8.5.1 Detailed list of key startups/SMEs 468 13.8.5.2 Competitive benchmarking of key startups/SMEs 470   13.9 COMPETITIVE SCENARIO 471 13.9.1 PRODUCT APPROVALS 471 13.9.2 DEALS 471 13.9.3 EXPANSIONS 473 14 COMPANY PROFILES 476 14.1 KEY PLAYERS 476 14.1.1 PFIZER INC. 476 14.1.1.1 Business overview 476 14.1.1.2 Products offered 477 14.1.1.3 Recent developments 479 14.1.1.3.1 Expansions 479 14.1.1.4 MnM view 480 14.1.1.4.1 Key strengths 480 14.1.1.4.2 Strategic choices 480 14.1.1.4.3 Weaknesses and competitive threats 480 14.1.2 DIVI’S LABORATORIES LIMITED 481 14.1.2.1 Business overview 481 14.1.2.2 Products offered 482 14.1.2.3 Recent developments 483 14.1.2.3.1 Deals 483 14.1.2.3.2 Expansions 484 14.1.2.4 MnM view 484 14.1.2.4.1 Key strengths 484 14.1.2.4.2 Strategic choices 484 14.1.2.4.3 Weaknesses and competitive threats 484 14.1.3 ASYMCHEM INC. 485 14.1.3.1 Business overview 485 14.1.3.2 Products offered 486 14.1.3.3 Recent developments 487 14.1.3.3.1 Deals 487 14.1.3.3.2 Expansions 487 14.1.3.4 MnM view 488 14.1.3.4.1 Key strengths 488 14.1.3.4.2 Strategic choices 488 14.1.3.4.3 Weaknesses and competitive threats 488 14.1.4 CIPLA 489 14.1.4.1 Business overview 489 14.1.4.2 Products offered 490 14.1.4.3 Recent developments 492 14.1.4.3.1 Deals 492 14.1.4.4 MnM view 492 14.1.4.4.1 Key strengths 492 14.1.4.4.2 Strategic choices 493 14.1.4.4.3 Weaknesses and competitive threats 493 14.1.5 EVONIK 494 14.1.5.1 Business overview 494 14.1.5.2 Products offered 495 14.1.5.3 Recent developments 496 14.1.5.3.1 Deals 496 14.1.5.3.2 Expansions 497 14.1.5.4 MnM view 498 14.1.5.4.1 Key strengths 498 14.1.5.4.2 Strategic choices 498 14.1.5.4.3 Weaknesses and competitive threats 498 14.1.6 TEVA PHARMACEUTICAL INDUSTRIES LTD. 499 14.1.6.1 Business overview 499 14.1.6.2 Products offered 500 14.1.6.3 Recent developments 509 14.1.6.3.1 Other developments 509 14.1.7 SANDOZ GROUP AG 510 14.1.7.1 Business overview 510 14.1.7.2 Products offered 511 14.1.7.3 Recent developments 513 14.1.7.3.1 Expansions 513 14.1.8 SK INC. 514 14.1.8.1 Business overview 514 14.1.8.2 Products offered 515 14.1.8.3 Recent developments 516 14.1.8.3.1 Deals 516 14.1.8.3.2 Expansions 516 14.1.9 MERCK KGAA 518 14.1.9.1 Business overview 518 14.1.9.2 Products offered 519 14.1.9.3 Recent developments 520 14.1.9.3.1 Deals 520 14.1.9.3.2 Expansions 521 14.1.10 DR. REDDY’S LABORATORIES LTD. 522 14.1.10.1 Business overview 522 14.1.10.2 Products offered 523 14.1.10.3 Recent developments 525 14.1.10.3.1 Expansions 525 14.1.10.3.2 Other developments 525   14.1.11 SUN PHARMACEUTICAL INDUSTRIES LTD. 526 14.1.11.1 Business overview 526 14.1.11.2 Products offered 527 14.1.11.3 Recent developments 529 14.1.11.3.1 Deals 529 14.1.12 AUROBINDO PHARMA LIMITED 530 14.1.12.1 Business overview 530 14.1.12.2 Products offered 531 14.1.12.3 Recent developments 532 14.1.12.3.1 Deals 532 14.1.13 HIKMA PHARMACEUTICALS PLC 533 14.1.13.1 Business overview 533 14.1.13.2 Products offered 534 14.1.13.3 Recent developments 535 14.1.13.3.1 Deals 535 14.1.13.3.2 Expansions 535 14.1.14 BASF 536 14.1.14.1 Business overview 536 14.1.14.2 Products offered 537 14.1.15 ALEMBIC PHARMACEUTICALS LIMITED 539 14.1.15.1 Business overview 539 14.1.15.2 Products offered 540 14.1.15.3 Recent developments 541 14.1.15.3.1 Product launches and approvals 541 14.1.16 SIEGFRIED HOLDING AG 542 14.1.16.1 Business overview 542 14.1.16.2 Products offered 543 14.1.16.3 Recent developments 544 14.1.16.3.1 Deals 544 14.1.16.3.2 Expansions 545 14.1.17 EUROAPI 546 14.1.17.1 Business overview 546 14.1.17.2 Products offered 547 14.1.17.3 Recent developments 547 14.1.17.3.1 Expansions 547 14.1.18 BACHEM 548 14.1.18.1 Business overview 548 14.1.18.2 Products offered 549 14.1.19 ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. 551 14.1.19.1 Business overview 551 14.1.19.2 Products offered 551   14.1.20 ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. 553 14.1.20.1 Business overview 553 14.1.20.2 Products offered 553 14.2 OTHER PLAYERS 555 14.2.1 POLYPEPTIDE GROUP 555 14.2.2 GRANULES INDIA 556 14.2.3 CORDEN PHARMA 557 14.2.4 RECIPHARM 558 14.2.5 ABURAIHAN PHARMACEUTICAL COMPANY 559 14.2.6 CURIA GLOBAL, INC. 560 14.2.7 CAMBREX CORPORATION 561 14.2.8 API PHARMA TECH 562 14.2.9 SREEPATHI PHARMACEUTICALS LIMITED 563 14.2.10 SHILPA MEDICARE LIMITED 564 14.2.11 NANJING JIANYOU BIOCHEMICAL PHARMACEUTICAL CO., LTD. 565 14.2.12 HOVIONE 566 14.2.13 CHEMCON GMBH 567 14.2.14 PHARCO PHARMACEUTICALS 567 14.2.15 SAMBI PHARMA PVT. LTD. 568 15 DISCUSSION GUIDE 569 15.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 574 15.2 CUSTOMIZATION OPTIONS 576 15.3 RELATED REPORTS 576 15.4 AUTHOR DETAILS 577
圖表清單 List of Tables & Figures
TABLE 1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCLUSIONS AND EXCLUSIONS 50 TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 64 TABLE 3 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: RISK ANALYSIS 67 TABLE 4 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 80 TABLE 5 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 83 TABLE 6 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVAL, 2024 87 TABLE 7 EUROPEAN DIRECTORATE FOR QUALITY OF MEDICINES & HEALTHCARE CERTIFICATE OF SUITABILITY TO MONOGRAPHS OF EUROPEAN PHARMACOPOEIA (EDQM CEP) CERTIFICATION ACTIVITY, 2024 88 TABLE 8 INDICATIVE PRICING OF ACTIVE PHARMACEUTICAL INGREDIENTS, BY KEY PLAYER, 2024 (USD) 94 TABLE 9 INDICATIVE PRICING ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2024 (USD) 95 TABLE 10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: ROLE IN ECOSYSTEM 103 TABLE 11 ACTIVE PHARMACEUTICAL INGREDIENTS: KEY CONFERENCES & EVENTS, 2025–2026 104 TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 108 TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 108 TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109 TABLE 15 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 110 TABLE 16 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 110 TABLE 17 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PORTER’S FIVE FORCES 111 TABLE 18 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 113 TABLE 19 BUYING CRITERIA FOR ACTIVE PHARMACEUTICAL INGREDIENTS, BY END USER 114 TABLE 20 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: CASE STUDY ANALYSIS 115 TABLE 21 HEALTH EXPENDITURE AND FINANCING, 2015–2024 (IN PERCENTAGE OF GDP) 116 TABLE 22 CANCER INCIDENCE, BY REGION, 2022 118 TABLE 23 NUMBER OF PATENTS FILED IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2014–2024 119 TABLE 24 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: LIST OF PATENTS, 2023 120 TABLE 25 IMPORT DATA FOR ANTIBIOTICS HS CODE–2941, 2020-2024, VALUE (USD) 121 TABLE 26 IMPORT DATA FOR ANTIBIOTICS HS CODE–2941, 2020-2024, VOLUME (TONS) 121 TABLE 27 IMPORT DATA FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCL. WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY) HS CODE–2934, 2020-2024, VALUE (USD) 122 TABLE 28 IMPORT DATA FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCL. WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY) HS CODE–2934, 2020-2024, VOLUME (TONS) 122 TABLE 29 IMPORT DATA FOR HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF "INCL. CHAIN MODIFIED POLYPEPTIDES", USED PRIMARILY AS HORMONES, HS CODE–2937, 2020-2024, VALUE (USD) 123 TABLE 30 IMPORT DATA FOR HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF "INCL. CHAIN MODIFIED POLYPEPTIDES", USED PRIMARILY AS HORMONES, HS CODE–2934, 2020-2024, VOLUME (TONS) 123 TABLE 31 EXPORT DATA FOR ANTIBIOTICS HS CODE–2941, 2020-2024, VALUE (USD) 124 TABLE 32 EXPORT DATA FOR ANTIBIOTICS HS CODE–2941, 2020-2024, VOLUME (TONS) 124 TABLE 33 EXPORT DATA FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCL. WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY) HS CODE–2934, 2020-2024, VALUE (USD) 125 TABLE 34 EXPORT DATA FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCL. WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY) HS CODE–2934, 2020-2024, VOLUME (TONS) 125 TABLE 35 EXPORT DATA FOR HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF "INCL. CHAIN MODIFIED POLYPEPTIDES", USED PRIMARILY AS HORMONE, HS CODE–2934, 2020-2024, VALUE (USD) 126 TABLE 36 EXPORT DATA FOR HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF "INCL. CHAIN MODIFIED POLYPEPTIDES", USED PRIMARILY AS HORMONES, HS CODE–2934, 2020-2024, VOLUME (TONS) 126 TABLE 37 MANUFACTURING SITES OF KEY API SUPPLIERS 128 TABLE 38 LIST OF SITE EXPANSIONS FOR API MANUFACTURERS, 2023–2025 130 TABLE 39 KEY COMPANIES IMPLEMENTING AI 133 TABLE 40 US ADJUSTED RECIPROCAL TARIFF RATES 134 TABLE 41 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 139 TABLE 42 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE (CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION) 139 TABLE 43 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 140 TABLE 44 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY REGION, 2023–2030 (USD BILLION) 141 TABLE 45 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2023–2030 (USD BILLION) 141 TABLE 46 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2023–2030 (USD BILLION) 142 TABLE 47 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2023–2030 (USD BILLION) 142 TABLE 48 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2023–2030 (USD BILLION) 143 TABLE 49 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2023–2030 (USD BILLION) 143 TABLE 50 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2023–2030 (USD BILLION) 143 TABLE 51 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY REGION, 2023–2030 (USD BILLION) 144 TABLE 52 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 145 TABLE 53 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 145 TABLE 54 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 146 TABLE 55 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 146 TABLE 56 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 146 TABLE 57 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 147 TABLE 58 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 149 TABLE 59 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY (CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION) 149 TABLE 60 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 150 TABLE 61 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY REGION, 2023–2030 (USD BILLION) 151 TABLE 62 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2023–2030 (USD BILLION) 151 TABLE 63 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2023–2030 (USD BILLION) 152 TABLE 64 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2023–2030 (USD BILLION) 152 TABLE 65 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2023–2030 (USD BILLION) 153 TABLE 66 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2023–2030 (USD BILLION) 153 TABLE 67 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2023–2030 (USD BILLION) 153 TABLE 68 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY TYPE, 2023–2030 (USD BILLION) 154 TABLE 69 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY REGION, 2023–2030 (USD BILLION) 155 TABLE 70 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2023–2030 (USD BILLION) 155 TABLE 71 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2023–2030 (USD BILLION) 156 TABLE 72 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2023–2030 (USD BILLION) 156 TABLE 73 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2023–2030 (USD BILLION) 157 TABLE 74 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2023–2030 (USD BILLION) 157 TABLE 75 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2023–2030 (USD BILLION) 157 TABLE 76 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY REGION, 2023–2030 (USD BILLION) 158 TABLE 77 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 159 TABLE 78 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 159 TABLE 79 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 160 TABLE 80 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 160 TABLE 81 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 160 TABLE 82 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 161 TABLE 83 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD BILLION) 162 TABLE 84 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD BILLION) 162 TABLE 85 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD BILLION) 163 TABLE 86 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD BILLION) 163 TABLE 87 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD BILLION) 164 TABLE 88 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD BILLION) 164 TABLE 89 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD BILLION) 164 TABLE 90 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 (USD BILLION) 166 TABLE 91 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION) 166 TABLE 92 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 (USD BILLION) 167 TABLE 93 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2023–2030 (USD BILLION) 168 TABLE 94 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 168 TABLE 95 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 169 TABLE 96 ASIA PACIFIC: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 169 TABLE 97 LATIN AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 170 TABLE 98 MIDDLE EAST: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 170 TABLE 99 GCC COUNTRIES: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 170 TABLE 100 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 171 TABLE 101 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY REGION, 2023–2030 (USD BILLION) 172 TABLE 102 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 172 TABLE 103 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 173 TABLE 104 ASIA PACIFIC: INACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 173 TABLE 105 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 174 TABLE 106 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 174 TABLE 107 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 174 TABLE 108 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY REGION, 2023–2030 (USD BILLION) 175 TABLE 109 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 176 TABLE 110 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 176 TABLE 111 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 177 TABLE 112 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 177 TABLE 113 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 178 TABLE 114 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION) 178 TABLE 115 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY REGION, 2023–2030 (USD BILLION) 179 TABLE 116 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION) 179 TABLE 117 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION) 180 TABLE 118 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION) 180 TABLE 119 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION) 181 TABLE 120 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION) 181 TABLE 121 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION) 181 TABLE 122 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 182 TABLE 123 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY REGION, 2023–2030 (USD BILLION) 183 TABLE 124 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION) 183 TABLE 125 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION) 184 TABLE 126 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION) 184 TABLE 127 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION) 185 TABLE 128 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION) 185 TABLE 129 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION) 185 TABLE 130 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY REGION, 2023–2030 (USD BILLION) 187 TABLE 131 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION) 187 TABLE 132 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION) 188 TABLE 133 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION) 188 TABLE 134 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION) 189 TABLE 135 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION) 189 TABLE 136 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION) 189 TABLE 137 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 190 TABLE 138 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD BILLION) 191 TABLE 139 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION) 191 TABLE 140 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION) 192 TABLE 141 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION) 192 TABLE 142 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION) 193 TABLE 143 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION) 193 TABLE 144 GCC COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION) 193 TABLE 145 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY REGION, 2023–2030 (USD BILLION) 194 TABLE 146 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY COUNTRY, 2023–2030 (USD BILLION) 194 TABLE 147 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET HORMONES AND GROWTH FACTORS, BY COUNTRY, 2023–2030 (USD BILLION) 195 TABLE 148 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY COUNTRY, 2023–2030 (USD BILLION) 195 TABLE 149 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY COUNTRY, 2023–2030 (USD BILLION) 196 TABLE 150 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY COUNTRY, 2023–2030 (USD BILLION) 196 TABLE 151 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY COUNTRY, 2023–2030 (USD BILLION) 196 TABLE 152 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY REGION, 2023–2030 (USD BILLION) 197 TABLE 153 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION) 197 TABLE 154 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION) 198 TABLE 155 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION) 198 TABLE 156 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION) 199 TABLE 157 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION) 199 TABLE 158 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION) 199 TABLE 159 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY REGION, 2023–2030 (USD BILLION) 200 TABLE 160 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2023–2030 (USD BILLION) 200 TABLE 161 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2023–2030 (USD BILLION) 201 TABLE 162 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2023–2030 (USD BILLION) 201 TABLE 163 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2023–2030 (USD BILLION) 202 TABLE 164 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2023–2030 (USD BILLION) 202 TABLE 165 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2023–2030 (USD BILLION) 202 TABLE 166 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2023–2030 (USD BILLION) 203 TABLE 167 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2030 (USD BILLION) 203 TABLE 168 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2030 (USD BILLION) 204 TABLE 169 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2030 (USD BILLION) 204 TABLE 170 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2030 (USD BILLION) 205 TABLE 171 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2030 (USD BILLION) 205 TABLE 172 GCC COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2030 (USD BILLION) 205 TABLE 173 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY REGION, 2023–2030 (USD BILLION) 206 TABLE 174 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY COUNTRY, 2023–2030 (USD BILLION) 206 TABLE 175 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY COUNTRY, 2023–2030 (USD BILLION) 207 TABLE 176 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY COUNTRY, 2023–2030 (USD BILLION) 207 TABLE 177 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY COUNTRY, 2023–2030 (USD BILLION) 208 TABLE 178 MIDDLE EAST: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY COUNTRY, 2023–2030 (USD BILLION) 208 TABLE 179 GCC COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY COUNTRY, 2023–2030 (USD BILLION) 208 TABLE 180 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY REGION, 2023–2030 (USD BILLION) 209 TABLE 181 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2030 (USD BILLION) 210 TABLE 182 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2030 (USD BILLION) 210 TABLE 183 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2030 (USD BILLION) 211 TABLE 184 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2030 (USD BILLION) 211 TABLE 185 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2030 (USD BILLION) 212 TABLE 186 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2030 (USD BILLION) 212 TABLE 187 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 213 TABLE 188 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD BILLION) 214 TABLE 189 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 214 TABLE 190 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 215 TABLE 191 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 215 TABLE 192 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 216 TABLE 193 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 216 TABLE 194 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 216 TABLE 195 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD BILLION) 217 TABLE 196 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 218 TABLE 197 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 218 TABLE 198 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 219 TABLE 199 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 219 TABLE 200 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 220 TABLE 201 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 220 TABLE 202 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD BILLION) 221 TABLE 203 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 221 TABLE 204 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 222 TABLE 205 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 222 TABLE 206 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 223 TABLE 207 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 223 TABLE 208 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 223 TABLE 209 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD BILLION) 225 TABLE 210 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 225 TABLE 211 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 226 TABLE 212 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 226 TABLE 213 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 227 TABLE 214 MIDDLE EAST: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 227 TABLE 215 GCC COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 227 TABLE 216 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD BILLION) 228 TABLE 217 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 228 TABLE 218 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 229 TABLE 219 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 229 TABLE 220 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 230 TABLE 221 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 230 TABLE 222 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION) 230 TABLE 223 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 232 TABLE 224 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG (CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION) 232 TABLE 225 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 233 TABLE 226 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY REGION, 2023–2030 (USD BILLION) 234 TABLE 227 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2030 (USD BILLION) 234 TABLE 228 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2030 (USD BILLION) 235 TABLE 229 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2030 (USD BILLION) 235 TABLE 230 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2030 (USD BILLION) 236 TABLE 231 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2030 (USD BILLION) 236 TABLE 232 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2030 (USD BILLION) 236 TABLE 233 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2023–2030 (USD BILLION) 237 TABLE 234 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2030 (USD BILLION) 238 TABLE 235 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER- THE-COUNTER DRUGS, BY COUNTRY, 2023–2030 (USD BILLION) 238 TABLE 236 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2030 (USD BILLION) 239 TABLE 237 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2030 (USD BILLION) 239 TABLE 238 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2030 (USD BILLION) 239 TABLE 239 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2030 (USD BILLION) 240 TABLE 240 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 242 TABLE 241 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION) 243 TABLE 242 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 243 TABLE 243 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2023–2030 (USD BILLION) 244 TABLE 244 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION) 245 TABLE 245 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION) 245 TABLE 246 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION) 246 TABLE 247 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION) 246 TABLE 248 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION) 247 TABLE 249 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION) 247 TABLE 250 LIST OF FDA-APPROVED DRUGS FOR DIFFERENT TYPES OF CANCER 248 TABLE 251 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD BILLION) 248 TABLE 252 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION) 249 TABLE 253 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION) 249 TABLE 254 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION) 250 TABLE 255 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION) 250 TABLE 256 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION) 250 TABLE 257 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION) 251 TABLE 258 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY REGION, 2023–2030 (USD BILLION) 252 TABLE 259 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD BILLION) 252 TABLE 260 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD BILLION) 253 TABLE 261 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD BILLION) 253 TABLE 262 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD BILLION) 254 TABLE 263 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD BILLION) 254 TABLE 264 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD BILLION) 254 TABLE 265 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2 TABLE 301 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2023–2030 (USD BILLION) 274 TABLE 302 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2023–2030 (USD BILLION) 275 TABLE 303 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023–2030 (USD BILLION) 276 TABLE 304 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 276 TABLE 305 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 277 TABLE 306 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 277 TABLE 307 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 278 TABLE 308 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 278 TABLE 309 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 278 TABLE 310 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2023–2030 (USD BILLION) 279 TABLE 311 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 280 TABLE 312 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 280 TABLE 313 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 281 TABLE 314 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 281 TABLE 315 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 281 TABLE 316 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 282 TABLE 317 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD BILLION) 283 TABLE 318 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION) 283 TABLE 319 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION) 284 TABLE 320 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION) 284 TABLE 321 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION) 285 TABLE 322 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION) 285 TABLE 323 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION) 285 TABLE 324 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2023–2030 (USD BILLION) 287 TABLE 325 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION (CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION) 288 TABLE 326 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2023–2030 (USD BILLION) 288 TABLE 327 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 290 TABLE 328 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 291 TABLE 329 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 291 TABLE 330 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 291 TABLE 331 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 292 TABLE 332 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 292 TABLE 333 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 292 TABLE 334 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 293 TABLE 335 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 293 TABLE 336 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 294 TABLE 337 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 294 TABLE 338 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 295 TABLE 339 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 295 TABLE 340 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 296 TABLE 341 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 297 TABLE 342 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 297 TABLE 343 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 297 TABLE 344 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 298 TABLE 345 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 298 TABLE 346 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 299 TABLE 347 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 299 TABLE 348 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 300 TABLE 349 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 300 TABLE 350 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 301 TABLE 351 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 302 TABLE 352 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 302 TABLE 353 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 302 TABLE 354 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 303 TABLE 355 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 303 TABLE 356 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 303 TABLE 357 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 304 TABLE 358 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 304 TABLE 359 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 305 TABLE 360 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 305 TABLE 361 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 306 TABLE 362 EUROPE: KEY MACROECONOMIC INDICATORS 307 TABLE 363 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 308 TABLE 364 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 308 TABLE 365 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 308 TABLE 366 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 309 TABLE 367 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 309 TABLE 368 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 309 TABLE 369 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 310 TABLE 370 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 310 TABLE 371 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 311 TABLE 372 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 311 TABLE 373 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 312 TABLE 374 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 312 TABLE 375 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 313 TABLE 376 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 314 TABLE 377 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 314 TABLE 378 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 314 TABLE 379 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 315 TABLE 380 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 315 TABLE 381 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 316 TABLE 382 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 316 TABLE 383 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 317 TABLE 384 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 317 TABLE 385 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 318 TABLE 386 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 319 TABLE 387 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 319 TABLE 388 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 319 TABLE 389 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 320 TABLE 390 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 320 TABLE 391 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 320 TABLE 392 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 321 TABLE 393 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 321 TABLE 394 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 322 TABLE 395 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 322 TABLE 396 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 323 TABLE 397 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 324 TABLE 398 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 324 TABLE 399 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 324 TABLE 400 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 325 TABLE 401 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 325 TABLE 402 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 325 TABLE 403 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 326 TABLE 404 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 326 TABLE 405 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 327 TABLE 406 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 327 TABLE 407 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 328 TABLE 408 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 328 TABLE 409 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 329 TABLE 410 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 329 TABLE 411 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 329 TABLE 412 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 330 TABLE 413 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 330 TABLE 414 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 331 TABLE 415 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 331 TABLE 416 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 332 TABLE 417 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 332 TABLE 418 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 333 TABLE 419 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 334 TABLE 420 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 334 TABLE 421 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 334 TABLE 422 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 335 TABLE 423 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 335 TABLE 424 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 335 TABLE 425 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 336 TABLE 426 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 336 TABLE 427 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 337 TABLE 428 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 337 TABLE 429 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 338 TABLE 430 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 339 TABLE 431 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 339 TABLE 432 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 339 TABLE 433 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 340 TABLE 434 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 340 TABLE 435 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 340 TABLE 436 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 341 TABLE 437 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 341 TABLE 438 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 342 TABLE 439 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 342 TABLE 440 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 343 TABLE 441 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 344 TABLE 442 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 344 TABLE 443 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 344 TABLE 444 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 345 TABLE 445 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 345 TABLE 446 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 345 TABLE 447 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 346 TABLE 448 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 346 TABLE 449 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 347 TABLE 450 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 347 TABLE 451 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 348 TABLE 452 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 350 TABLE 453 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 350 TABLE 454 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 351 TABLE 455 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 351 TABLE 456 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 351 TABLE 457 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 352 TABLE 458 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 352 TABLE 459 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 352 TABLE 460 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 353 TABLE 461 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 353 TABLE 462 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 354 TABLE 463 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 354 TABLE 464 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 355 TABLE 465 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 356 TABLE 466 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 356 TABLE 467 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 356 TABLE 468 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 357 TABLE 469 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 357 TABLE 470 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 357 TABLE 471 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 358 TABLE 472 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 358 TABLE 473 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 359 TABLE 474 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 359 TABLE 475 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 360 TABLE 476 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 361 TABLE 477 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 361 TABLE 478 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 361 TABLE 479 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 362 TABLE 480 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 362 TABLE 481 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 362 TABLE 482 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 363 TABLE 483 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 363 TABLE 484 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 364 TABLE 485 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 364 TABLE 486 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 365 TABLE 487 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 366 TABLE 488 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 366 TABLE 489 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 366 TABLE 490 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 367 TABLE 491 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 367 TABLE 492 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 367 TABLE 493 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 368 TABLE 494 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 368 TABLE 495 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 369 TABLE 496 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 369 TABLE 497 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 370 TABLE 498 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 371 TABLE 499 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 371 TABLE 500 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 371 TABLE 501 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 372 TABLE 502 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 372 TABLE 503 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 372 TABLE 504 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 373 TABLE 505 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 373 TABLE 506 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 374 TABLE 507 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 374 TABLE 508 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 375 TABLE 509 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 376 TABLE 510 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 376 TABLE 511 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 376 TABLE 512 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 377 TABLE 513 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 377 TABLE 514 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 377 TABLE 515 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 378 TABLE 516 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 378 TABLE 517 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 379 TABLE 518 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 379 TABLE 519 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 380 TABLE 520 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 381 TABLE 521 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 381 TABLE 522 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 381 TABLE 523 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 382 TABLE 524 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 382 TABLE 525 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 382 TABLE 526 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 383 TABLE 527 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 383 TABLE 528 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 384 TABLE 529 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 384 TABLE 530 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 385 TABLE 531 LATIN AMERICA: KEY MACRO INDICATORS 386 TABLE 532 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 386 TABLE 533 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 387 TABLE 534 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 387 TABLE 535 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 387 TABLE 536 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 388 TABLE 537 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 388 TABLE 538 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 388 TABLE 539 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 389 TABLE 540 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 389 TABLE 541 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 390 TABLE 542 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 390 TABLE 543 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 391 TABLE 544 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 392 TABLE 545 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 392 TABLE 546 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 392 TABLE 547 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 393 TABLE 548 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 393 TABLE 549 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 393 TABLE 550 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 394 TABLE 551 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 394 TABLE 552 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 395 TABLE 553 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 395 TABLE 554 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 396 TABLE 555 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 397 TABLE 556 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 397 TABLE 557 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 397 TABLE 558 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 398 TABLE 559 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 398 TABLE 560 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 398 TABLE 561 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 399 TABLE 562 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 399 TABLE 563 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 400 TABLE 564 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 400 TABLE 565 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 401 TABLE 566 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 401 TABLE 567 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 402 TABLE 568 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 402 TABLE 569 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 402 TABLE 570 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 403 TABLE 571 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 403 TABLE 572 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 404 TABLE 573 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 404 TABLE 574 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 405 TABLE 575 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 405 TABLE 576 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 406 TABLE 577 MIDDLE EAST: KEY MACROECONOMIC INDICATORS 407 TABLE 578 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 407 TABLE 579 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 408 TABLE 580 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 408 TABLE 581 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 408 TABLE 582 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 409 TABLE 583 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 409 TABLE 584 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 409 TABLE 585 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 410 TABLE 586 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 410 TABLE 587 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 411 TABLE 588 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 411 TABLE 589 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 412 TABLE 590 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 412 TABLE 591 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 413 TABLE 592 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 413 TABLE 593 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 413 TABLE 594 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 414 TABLE 595 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 414 TABLE 596 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 415 TABLE 597 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 415 TABLE 598 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 416 TABLE 599 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 416 TABLE 600 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 417 TABLE 601 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 417 TABLE 602 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 418 TABLE 603 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 418 TABLE 604 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 418 TABLE 605 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 419 TABLE 606 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 419 TABLE 607 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 419 TABLE 608 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 420 TABLE 609 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 420 TABLE 610 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 421 TABLE 611 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 421 TABLE 612 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 422 TABLE 613 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 423 TABLE 614 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 423 TABLE 615 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 423 TABLE 616 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 424 TABLE 617 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 424 TABLE 618 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 424 TABLE 619 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 425 TABLE 620 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 425 TABLE 621 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 426 TABLE 622 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 426 TABLE 623 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 427 TABLE 624 UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 428 TABLE 625 UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 428 TABLE 626 UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 428 TABLE 627 UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 429 TABLE 628 UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 429 TABLE 629 UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 429 TABLE 630 UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 430 TABLE 631 UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 430 TABLE 632 UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 431 TABLE 633 UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 431 TABLE 634 UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 432 TABLE 635 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 433 TABLE 636 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 433 TABLE 637 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 433 TABLE 638 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 434 TABLE 639 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 434 TABLE 640 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 434 TABLE 641 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 435 TABLE 642 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 435 TABLE 643 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 436 TABLE 644 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 436 TABLE 645 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 437 TABLE 646 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 438 TABLE 647 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 438 TABLE 648 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 438 TABLE 649 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 439 TABLE 650 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 439 TABLE 651 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 439 TABLE 652 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 440 TABLE 653 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 440 TABLE 654 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 441 TABLE 655 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 441 TABLE 656 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 442 TABLE 657 AFRICA: KEY MACROECONOMIC INDICATORS 443 TABLE 658 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 443 TABLE 659 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION) 444 TABLE 660 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 444 TABLE 661 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION) 444 TABLE 662 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION) 445 TABLE 663 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 445 TABLE 664 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION) 446 TABLE 665 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 446 TABLE 666 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION) 447 TABLE 667 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 447 TABLE 668 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION) 448 TABLE 669 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, JANUARY 2022–OCTOBER 2025 450 TABLE 670 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DEGREE OF COMPETITION 453 TABLE 671 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: REGION FOOTPRINT 461 TABLE 672 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: TYPE FOOTPRINT 462 TABLE 673 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: POTENCY FOOTPRINT 463 TABLE 674 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: THERAPEUTIC APPLICATION FOOTPRINT 464 TABLE 675 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 468 TABLE 676 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS, BY TYPE AND REGION 470 TABLE 677 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PRODUCT APPROVALS, JANUARY 2022–OCTOBER 2025 471 TABLE 678 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DEALS, JANUARY 2022–OCTOBER 2025 471 TABLE 679 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: EXPANSIONS, JANUARY 2022–OCTOBER 2025 473 TABLE 680 PFIZER INC.: COMPANY OVERVIEW 476 TABLE 681 PFIZER INC.: PRODUCTS OFFERED 477 TABLE 682 PFIZER INC.: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 479 TABLE 683 DIVI'S LABORATORIES LIMITED: COMPANY OVERVIEW 481 TABLE 684 DIVI'S LABORATORIES LIMITED: PRODUCTS OFFERED 482 TABLE 685 DIVI'S LABORATORIES LIMITED: DEALS, JANUARY 2022–SEPTEMBER 2025 483 TABLE 686 DIVI'S LABORATORIES LIMITED: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 484 TABLE 687 ASYMCHEM INC.: COMPANY OVERVIEW 485 TABLE 688 ASYMCHEM INC.: PRODUCTS OFFERED 486 TABLE 689 ASYMCHEM INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 487 TABLE 690 ASYMCHEM INC.: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 487 TABLE 691 CIPLA: COMPANY OVERVIEW 489 TABLE 692 CIPLA: PRODUCTS OFFERED 490 TABLE 693 CIPLA: DEALS, JANUARY 2022–SEPTEMBER 2025 492 TABLE 694 EVONIK: COMPANY OVERVIEW 494 TABLE 695 EVONIK: PRODUCTS OFFERED 495 TABLE 696 EVONIK: DEALS, JANUARY 2022–SEPTEMBER 2025 496 TABLE 697 EVONIK: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 497 TABLE 698 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 499 TABLE 699 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 500 TABLE 700 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025 509 TABLE 701 SANDOZ GROUP AG: COMPANY OVERVIEW 510 TABLE 702 SANDOZ GROUP AG: PRODUCTS OFFERED 511 TABLE 703 SANDOZ GROUP AG: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 513 TABLE 704 SK INC.: COMPANY OVERVIEW 514 TABLE 705 SK INC.: PRODUCTS OFFERED 515 TABLE 706 SK INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 516 TABLE 707 SK INC.: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 516 TABLE 708 MERCK KGAA: COMPANY OVERVIEW 518 TABLE 709 MERCK KGAA: PRODUCTS OFFERED 519 TABLE 710 MERCK KGAA: DEALS, JANUARY 2022–SEPTEMBER 2025 520 TABLE 711 MERCK KGAA: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 521 TABLE 712 DR. REDDY’S LABORATORIES LTD.: COMPANY OVERVIEW 522 TABLE 713 DR. REDDY’S LABORATORIES LTD.: PRODUCTS OFFERED 523 TABLE 714 DR. REDDY’S LABORATORIES LTD.: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 525 TABLE 715 DR. REDDY’S LABORATORIES LTD.: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025 525 TABLE 716 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 526 TABLE 717 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 527 TABLE 718 SUN PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022–SEPTEMBER 2025 529 TABLE 719 AUROBINDO PHARMA LIMITED: COMPANY OVERVIEW 530 TABLE 720 AUROBINDO PHARMA: PRODUCTS OFFERED 531 TABLE 721 AUROBINDO PHARMA: DEALS, JANUARY 2022–SEPTEMBER 2025 532 TABLE 722 HIKMA PHARMACEUTICALS PLC: COMPANY OVERVIEW 533 TABLE 723 HIKMA PHARMACEUTICALS PLC: PRODUCTS OFFERED 534 TABLE 724 HIKMA PHARMACEUTICALS PLC: DEALS, JANUARY 2022–SEPTEMBER 2025 535 TABLE 725 HIKMA PHARMACEUTICALS PLC: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 535 TABLE 726 BASF: COMPANY OVERVIEW 536 TABLE 727 BASF: PRODUCTS OFFERED 537 TABLE 728 ALEMBIC PHARMACEUTICALS LIMITED: COMPANY OVERVIEW 539 TABLE 729 ALEMBIC PHARMACEUTICALS LIMITED: PRODUCTS OFFERED 540 TABLE 730 ALEMBIC PHARMACEUTICALS LIMITED: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–SEPTEMBER 2025 541 TABLE 731 SIEGFRIED HOLDING AG: COMPANY OVERVIEW 542 TABLE 732 SIEGFRIED HOLDING AG: PRODUCTS OFFERED 543 TABLE 733 SIEGFRIED HOLDING AG: DEALS, JANUARY 2022–SEPTEMBER 2025 544 TABLE 734 SIEGFRIED HOLDING AG: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 545 TABLE 735 EUROAPI: COMPANY OVERVIEW 546 TABLE 736 EUROAPI: PRODUCTS OFFERED 547 TABLE 737 EUROAPI: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 547 TABLE 738 BACHEM: COMPANY OVERVIEW 548 TABLE 739 BAYCHEM: PRODUCTS OFFERED 549 TABLE 740 ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW 551 TABLE 741 ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED 551 TABLE 742 ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW 553 TABLE 743 ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED 553 TABLE 744 POLYPEPTIDE GROUP: COMPANY OVERVIEW 555 TABLE 745 GRANULES INDIA: COMPANY OVERVIEW 556 TABLE 746 CORDEN PHARMA: COMPANY OVERVIEW 557 TABLE 747 RECIPHARMA: COMPANY OVERVIEW 558 TABLE 748 ABURAIHAN PHARMACEUTICAL COMPANY: COMPANY OVERVIEW 559 TABLE 749 CURIA GLOBAL, INC.: COMPANY OVERVIEW 560 TABLE 750 CAMBREX CORPORATION: COMPANY OVERVIEW 561 TABLE 751 API PHARMA TECH: COMPANY OVERVIEW 562 TABLE 752 SREEPATHI PHARMACEUTICALS LIMITED: COMPANY OVERVIEW 563 TABLE 753 SHILPA MEDICARE LIMITED: COMPANY OVERVIEW 564 TABLE 754 NANJING JIANYOU BIOCHEMICAL PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW 565 TABLE 755 HOVIONE: COMPANY OVERVIEW 566 TABLE 756 CHEMCON GMBH: COMPANY OVERVIEW 567 TABLE 757 PHARCO PHARMACEUTICALS: COMPANY OVERVIEW 567 TABLE 758 SAMBI PHARMA PVT. LTD.: COMPANY OVERVIEW 568 FIGURE 1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION & REGIONAL SCOPE 51 FIGURE 2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: YEARS CONSIDERED 52 FIGURE 3 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: RESEARCH DESIGN 54 FIGURE 4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: KEY DATA FROM SECONDARY SOURCES 56 FIGURE 5 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 57 FIGURE 6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 58 FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH, 2024 59 FIGURE 8 REVENUE SHARE ANALYSIS OF PFIZER, INC., 2024 59 FIGURE 9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE VALIDATION FROM PRIMARY SOURCES 61 FIGURE 10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: TOP-DOWN APPROACH 62 FIGURE 11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: CAGR PROJECTIONS 63 FIGURE 12 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DATA TRIANGULATION 65 FIGURE 13 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2025 VS. 2030 (USD BILLION) 70 FIGURE 14 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2025 VS. 2030 (USD BILLION) 70 FIGURE 15 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2025 VS. 2030 (USD BILLION) 71 FIGURE 16 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2025 VS. 2030 (USD BILLION) 71 FIGURE 17 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2025 VS. 2030 (USD BILLION) 72 FIGURE 18 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2025 VS. 2030 (USD BILLION) 73 FIGURE 19 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2025–2030 74 FIGURE 20 INCREASING DRUG R&D PIPELINE AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 76 FIGURE 21 INNOVATIVE APIS AND US TO LEAD NORTH AMERICAN MARKET IN 2025 77 FIGURE 22 SYNTHETIC SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 77 FIGURE 23 MONOCLONAL ANTIBODIES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 78 FIGURE 24 CHINA TO LEAD MARKET DURING FORECAST PERIOD 78 FIGURE 25 EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 79 FIGURE 26 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 82 FIGURE 27 GLOBAL PHARMACEUTICAL R&D SPENDING, 2023–2030, (USD BILLION) 86 FIGURE 28 NEW REVENUE POCKETS FOR PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 93 FIGURE 29 INDICATIVE PRICING ANALYSIS OF API, BY TYPE, 2024 95 FIGURE 30 INDICATIVE PRICING ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2024 96 FIGURE 31 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: SUPPLY CHAIN ANALYSIS 99 FIGURE 32 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: VALUE CHAIN ANALYSIS 101 FIGURE 33 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: ECOSYSTEM ANALYSIS 102 FIGURE 34 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PORTER’S FIVE FORCES ANALYSIS 111 FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE 113 FIGURE 36 KEY BUYING CRITERIA FOR END USERS 114 FIGURE 37 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024 119 FIGURE 38 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INVESTMENT AND FUNDING SCENARIO, 2025 (USD MILLION) 127 FIGURE 39 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: AI USE CASES 132 FIGURE 40 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 289 FIGURE 41 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 349 FIGURE 42 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2022–2024 (USD MILLION) 451 FIGURE 43 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 453 FIGURE 44 EV/EBITDA OF KEY VENDORS 455 FIGURE 45 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: BRAND/PRODUCT COMPARISON 457 FIGURE 46 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 459 FIGURE 47 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY FOOTPRINT 460 FIGURE 48 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 467 FIGURE 49 PFIZER INC.: COMPANY SNAPSHOT (2024) 477 FIGURE 50 DIVI'S LABORATORIES LIMITED: COMPANY SNAPSHOT (2024) 481 FIGURE 51 ASYMCHEM INC.: COMPANY SNAPSHOT (2024) 486 FIGURE 52 CIPLA: COMPANY SNAPSHOT (2024) 490 FIGURE 53 EVONIK: COMPANY SNAPSHOT (2024) 495 FIGURE 54 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024) 500 FIGURE 55 SANDOZ GROUP AG: COMPANY SNAPSHOT (2024) 511 FIGURE 56 SK INC.: COMPANY SNAPSHOT (2024) 515 FIGURE 57 MERCK KGAA: COMPANY SNAPSHOT (2024) 519 FIGURE 58 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2024) 523 FIGURE 59 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024) 527 FIGURE 60 AUROBINDO PHARMA LIMITED: COMPANY SNAPSHOT (2024) 531 FIGURE 61 HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2024) 534 FIGURE 62 BASF: COMPANY SNAPSHOT (2024) 537 FIGURE 63 ALEMBIC PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2024) 540 FIGURE 64 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2024) 543 FIGURE 65 EUROAPI: COMPANY SNAPSHOT (2024) 546 FIGURE 66 BAYCHEM: COMPANY SNAPSHOT (2024) 549

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們